Abstract: The present invention relates to an anhydrous colored cosmetic powder comprising at least one natural or synthetic silicate and at least one dye. During its preparation, such a powder may have contacted an aqueous phase which has subsequently been dried and is not present in its final state. The present invention also relates to a cosmetic composition comprising an aqueous phase and a non-aqueous phase comprising at least one colored powder portion, where the colored powder portion comprises at least one natural or synthetic silicate and at least one dye.

Abstract: The invention relates to new anti-wrinkle and anti-aging nanoformulations, composed of non-toxic mesoporous silica nanoparticles, natural plant extracts (as the case may be: pomegranate oil, fennel oil, rosemary oil, chamomile oil, jojoba oil, rosehip oil), biological active agents (acetyl hexapeptide-8, aspartic acid), vitamins and others. Additionally, the present invention relates a new method for preparing the nanoformulations by co-encapsulating its active agents within a multilayer nanocarrier, thereby, enhancing their delivery through the skin barrier and their controlled accumulation at the desired site. In certain embodiments, the active molecules are co-incorporated into an inner polymeric shell (silica derivatives) and onto its surface, followed by, the protection of an outer layer of chitosan-TAT (GRKKRRQRRRPQ). The active ingredients are crossed through the skin barrier using the disclosed delivery system to promote cell growth, skin rejuvenation and wrinkle removal.

Abstract: The invention describes novel compositions and methods utilized for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include hyperhidrosis, bromhidrosis, and chromhidrosis, One representative composition of the invention comprises; water, alcohol, aluminum sesquichlorohydrate, hydroxypropyl methyl cellulose, polysorbate 20, isopropyl myristate, eucalyptus oil, silicone oil, alkyl benzoate, glycerine, talc, a hydrophillic silica, a hydrophobic silica, phenoxyethanol and ethylhexyl glycerine.

Abstract: Zinc oxide compositions as well as techniques for plasmonic enhancement of absorption in sunscreen applications are provided herein. A method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles; and embedding the one or more selected metal particles into each of the one or more zinc oxide particles.

Abstract: The present invention is directed a shampoo composition for hair frizz reduction comprising from about 0.1% to about 20% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following: Class II having the structure selected from: a) wherein R is hydrogen or metal ion, R6 is methyl, ethyl, propyl, alkenyl or phenyl having less than 12 carbon atoms and wherein R7, R8, R9, R10, R11, R12 are hydrogen, methyl, ethyl, propyl, phenyl, hydroxyl, methoxy or ethoxy groups; b) an alcohol wherein R13 is an alkyl, alkenyl, straight or branched carbon chains and; and wherein R14 is hydrogen, hydroxyl, alkyl, methyl, ethyl and propyl wherein the structure of such alcohol contains less than 20 total carbon atoms; c) alcohol comprising an unsaturated double bond in the C2 position.

Abstract: The present invention is directed to a shampoo composition for hair frizz reduction comprising from about 0.1% to about 20% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following: wherein R? is —COOY, sulfonic acid, or C?CH—COOY, Y is hydrogen or a metal ion, R1, R2, R3, R4, R5 is hydrogen, methyl, ethyl, propyl, vinyl, allyl, methoxy, ethoxy, hydroxyl, halogen, sulfate, sulfonate, nitro, or —CH?CH—COOR, and wherein the moisture control material is an acidic material and further wherein the moisture control material has a % Protein binding higher than 20 and Molecular Volume lower than 500 and Partition coefficient octanol to water (log P) lower than 3 and hydrogen binding higher than 10 and pKa lower than 5.0.

Abstract: The present invention relates to treatment of various disorders, diseases or conditions associated with or mediated by oxidative stress arising from an imbalance between the production of and the ability to neutralize reactive free radicals. The present invention is directed to methods and compositions capable of scavenging reactive free radicals for therapeutically or prophylactically treating disorders associated with free radical-induced damage, said compositions comprising an amount of 2-(3-chlorophenylamino) phenylacetic acid (23CPPA) or a pharmaceutically acceptable salt thereof that interacts with free radicals generated by cellular metabolism or ultraviolet radiation. In some embodiments, the composition comprises pharmaceutically or cosmetically acceptable adjuncts. The present invention further provides one or more kits that are useful for delaying, treating or preventing the consequences of aging and free radical damage on the condition or appearance of the skin.

Abstract: A method is disclosed for reducing hair frizz by treating hair with a regimen comprising two or more hair care compositions wherein at least two of such compositions comprise Moisture Control Materials. Two or more of the compositions used in the method comprise from about 0.1% to about 20% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from the group consisting of Class I and Class II.

Abstract: The present invention relates to the use of a cosmetic composition comprising isosorbide monooleate for depositing isosorbide monooleate on human skin or hair. Furthermore it relates to a process for depositing isosorbide monooleate on human skin or hair, wherein this process comprises contacting human skin or hair with a cosmetic composition comprising isosorbide monooleate and rinsing off the cosmetic composition comprising isosorbide monooleate with water, so that, after rinsing off the cosmetic composition, isosorbide monooleate is left deposited on the human skin or hair.

Abstract: Disclosed herein are methods of promoting the aggregation and/or immune clearance of oral bacteria using oral care compositions comprising metal-amino acid complexes.

Abstract: The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: —Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 and NR1R2; —R1 and R2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; —Pro* correspond to a Proline, an analogue or derivative thereof; —if X is H then Y is selected from OR1, NH2, NHR1 and NR1R2, and if Y is OH then X is —CO— or —SO2—R1; and the peptide hypoxanthine-Pro-Pro-Arg being excluded.

Abstract: The inventive subject is directed towards ready-to-use topical cosmetic formulations that include at least one defensin present in sub-antimicrobially effective concentrations. Surprisingly, even at such low concentrations, defensins recruit LGR6+ stem cells from hair follicles to the interfollicular space. Including defensins in the inventive topical cosmetic formulations may reduce one or more of wrinkle depth, wrinkle length, wrinkle width, pore size, irregularity in texture of a skin surface, oiliness, brown spots, and red spots in non-injured skin, thus reducing apparent age.

Abstract: A cosmetic composition containing as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide is provided. In particular, a composition wherein the mu-conotoxin peptide is Arginine, lysine polypeptide (INCI name: pyroglutamyl s-mu-conotoxin CnIIIc amide acetate), CAS Number: 937286-43-6 (renumbered 936616-33-0), Molecular formula C92,H139,N35,O28,S6 acetate salt (molar mass 2376 g/mol.) is provided. The composition can be used to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Abstract: The invention relates to an antiperspirant cosmetic including at least one specific design protein and which is exempt of aluminum and/or zirconium halides and/or hydroxy halides. The invention further relates to the use of a specific protein and to a non-therapeutic method for reducing body perspiration. Adding or using said at least one specific protein ensures that the sweat gland(s) is/are effectively influenced, thus resulting in a significant reduction in axillary hyperhidrosis even in the absence of antiperspirant aluminum salts.

Abstract: Provided herein are growth factor concentrates, the method of preparing the growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates include decapsulated growth factors derived from platelet rich plasma.

Abstract: The present invention relates to the use of a lupin peptide extract to prevent loss of skin firmness or to increase the firmness of skin. Advantageously, the lupin peptide extract can prevent the appearance of cellulite and/or reduce skin cellulite.

Abstract: Methods for reducing the appearance of wrinkles in a subject are provided herein. The methods of the present invention comprise identifying a wrinkle distribution on a subject and applying a topical composition comprising at least one chemodenervating agent onto and along the wrinkle distribution. The methods disclosed herein provide alternative methods for delivery of chemodenervating agents to the skin for the treatment of wrinkles.

Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.

Abstract: The present invention relates to a photocurable composition for coating a nail or an artificial nail, including: a component (A): an acrylate oligomer; a component (B): a methacrylate monomer; and a component (C): a photopolymerization initiator. The present invention provides a photocurable composition for coating a nail or an artificial nail, which has a small amount of heat generation during curing by light irradiation.

Abstract: A method for dyeing keratin fibers, in particular human hair, in which, after a thickened pretreatment agent (M1) including at least one oxidation dye precursor has been applied and left to act, directly thereafter and without rinsing a coloring agent (M2) is applied and left to act. By virtue of this method, in one dyeing step the hair can be colored and at the same time a multi-tonal dyeing with lighter (“highlights”) or darker (“lowlights”) sections (strands) can be produced.

Abstract: A method for dyeing keratinous fibers, in particular, human hair, in which, after a thickened pre-treatment agent (M1) containing no oxidation dye precursors has been applied and allowed to react, a coloring agent (M2) is applied and allowed to react immediately thereafter and without rinsing. By carrying out said method, hair can be colored in a dyeing step and simultaneously multi-tonal dyeing with highlights or lowlights can be achieved.

Abstract: The subject of the present invention is an antiperspirant composition for personal body care with an improved residue behavior, which includes a mixture of at least one volatile silicone oil, PPG-14 butyl ether, and at least one other oil, selected from 2-phenoxyethyl octanoate and PPG-3 myristyl ether.

Abstract: This invention relates to the use of hydrophilic-rich, rake-type alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymers. A hydrophilic-rich alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymer is hereby defined as an alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymer possessing sufficient hydrophilic content such that it can be readily taken up by water at a concentration of at least 15% by mass copolymer with simple stirring at room temperature to yield a stable dispersion of micron and sub-micron sized particles. This definition supercedes the typical values of the formula variables x, y, z, q, and p specified above to include all values that result in the copolymer being hydrophilic-rich. This definition also supercedes the typical identity of R=dodecyl shown above to include R being any alkyl or branched-alkyl chain of any length such that the resulting copolymer is hydrophilic-rich.

Abstract: The composition according to one embodiment of the present invention includes red pepper extract; and at least one extract selected from the group consisting of cabbage extract, broccoli extract, radish extract, and cauliflower extract, and can give thermal sensation, treat damaged hair, and improve hair condition. Furthermore, it is possible to care hair easily in house by using the hair pack to which the composition is applied.

Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.

Abstract: A method of regulating mammalian keratinous tissue that includes applying a safe and effective amount of achachariu to a target portion of keratinous tissue. The achachariu can be in the form of a bioactive ingredient that exhibits anti-inflammatory, anti-oxidant, anti-aging, and/or anti-protein loss properties, and which is free or substantially free of benzophenones and/or protein. The achachariu ingredient may be a serum fraction and/or an extract, and may be incorporated into a personal care composition formulated for topical use on skin and/or hair.

Abstract: Personal care compositions that include bioactive ingredients derived from achachariu and methods of making the same. The bioactive compositions (ingredients) of the present invention may be free of or substantially free of benzophenones and/or protein, and may exhibit anti-inflammatory, anti-oxidant, anti-aging, and/or anti-protein loss properties. The achachariu ingredient may be in the form of a serum fraction and/or an extract. The personal care compositions are formulated for topical use on skin and/or hair.

Abstract: A method of regulating a skin conditions that includes applying a safe and effective amount of achachariu to a target portion of skin in need of treatment or where treatment is desired. The achachariu can be in the form of a bioactive ingredient that exhibits anti-inflammatory, anti-oxidant, and/or anti-aging properties, and which is free or substantially free of benzophenones and/or protein. The achachariu ingredient may be a serum fraction and/or an extract, and may be incorporated into a skin care composition formulated for topical use on skin.

Abstract: Topical skin care compositions that include bioactive ingredients derived from achachariu and methods of making the same. The bioactive compositions (ingredients) of the present invention may be free of or substantially free of benzophenones and/or protein, and may exhibit anti-inflammatory, anti-oxidant, and/or anti-aging properties. The achachariu ingredient may be in the form of a serum fraction and/or an extract.

Abstract: Described are methods for treating a keratinized tissue condition in a subject in need thereof. The method may include providing the subject including the keratinized tissue condition. The method may include conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with an acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue. The one or more treatment cycles may be effective to at least partly ameliorate the keratinized tissue condition in the subject.

Abstract: The invention relates to an anhydrous mixture of biologically active probiotic bacteria for topical administration and methods of making thereof. The mixture of the invention is used for hydrating the skin, reducing and preventing fine lines and wrinkles, treating acne and decreasing skin inflammation.

Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.

Abstract: A transdermal delivery system of microneedles containing a bioactive material, comprising at least one layer of a support material; at least one biodegradable needle associated with the support material, each needle comprising at least one biodegradable polymer and at least one sugar, wherein each biodegradable needle is hollow and is adapted to retain a bioactive material.

Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.

Abstract: A method to provide a therapeutic agent to an eye of a patient.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid in an acid or a salt form, can be used to treat or alleviate pain or related conditions.

Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Abstract: An orally dissolvable cannabis tablet includes one or more active cannabis-based chemical constituents and one or more inactive constituents. The active cannabis-based chemical constituents includes at least one of cannabinoids or terpenoids.

Abstract: A method for treating a prenatal, pregnant or breastfeeding patient for a disease, condition or disorder that is associated with a nutritional deficiency in the patient comprising administering at least one gummy composition to a patient. The gummy composition comprises an effective amount of vitamin A, vitamin B6, vitamin B12, vitamin B9, vitamin C, vitamin D, vitamin E, vitamin B3, iodine, choline, iron, and at least one omega-3 fatty acid to treat the disease, condition or disorder in the patient that is associated with a nutritional deficiency in the patient. The gummy composition is provided in a single, homogeneous mixture which is elastic, continuous and readily soluble in aqueous media.

Abstract: The present disclosure provides a device for self-preparation of a gastroretentive dosage form being capable of transitioning between a collapsed configuration and an expanded configuration, the device comprising an assembly unit including: a compartment configured for accommodating the gastroretentive dosage form in the expanded configuration; and a mechanical system configured for, upon operation of an actuation mechanism: (a) transitioning said gastroretentive dosage form into the collapsed configuration; and (b) locking said collapsed gastroretentive dosage form into the collapsed configuration; wherein the device is configured for being portable.

Abstract: The present invention relates to a simple, robust and effective process for preparing a dry powder inhalation formulation containing at least one drug, preferably a highly active drug, more preferably Tiotropium bromide or Tiotropium bromide monohydrate, and a lactose carrier. The process is characterized in that a three-layered composition containing a drug layer in between layers of the lactose carrier is mixed and the obtained preblend is mixed with additional lactose carrier. The process combines a simple manufacturing procedure with an excellent content uniformity obtained over a wide range of mixing parameters.

Abstract: An object is to provide an apparatus and method for generating a hydrogen-containing liquid that are capable of generating a hydrogen-containing liquid of which the hydrogen concentration after 10 minutes exceeds 6 ppm and the hydrogen concentration after 24 hours exceeds 10 ppm. The apparatus comprises a hydrogen generating agent (11) reacting with water to generate hydrogen gas, a capsule (20) configured to be charged with the hydrogen generating agent (11) and discharge the hydrogen gas generated in the capsule (20) to external, and a container (3) configured to be charged with a liquid (L) that is an object to which the hydrogen gas generated in the capsule (20) is added. The ratio (V/W) of a volume (V ml) of the capsule (20) to a weight (W g) of the hydrogen generating agent (11) is 11.4 or less and more preferably 8.2 or less.

Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.

Abstract: The invention relates in particular to an injectable sclerosant drug foam comprising: (i) a matrix; (ii) at least one fluid; (iii) at least one sclerosant drug; (iv) a medical gas or medical gas mixture acceptable for intravenous use, (v) wherein said matrix has physical properties, which are comparable to denatured blood, wherein the denatured blood is obtainable from a fresh human venous whole blood sample of 1 ml volume, which is heated in a cylindrical polyethylene container with 3 mm inner diameter and 3.4 mm outer diameter for about 0.5 min. to about 10 min. at a temperature of about between 70° C. and 100° C. and/or (vii) said level of denaturation is defined by the change of red-colored hemoglobin to brown as an indicator, wherein Fe2+ is reduced to Fe3+ in the hemoglobin complex to a degree of at least 80%, preferably 90% and even more preferably 95%.

Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

Abstract: The invention provides coated particles with a taste-masked drug substance. The particles comprise a core with the agglomerated active ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby preventing the degradation of the thermolabile active ingredient.

Abstract: The present invention is a technical filed of pharmaceutical preparation agent, and more particular to a pharmaceutical composition containing docetaxe. The pharmaceutical composition containing docetaxe includes docetaxel and a polyethylene glycol methyl ether-polylactide block copolymer with amino acid end groups. The advantage of the present invention is subjected to a tri-block copolymer with low toxicity as the drug carrier. In addition to the pharmaceutical active ingredients and carrier, there is no other additive in pharmaceutical composition containing docetaxe. Thus, the prescription is simpler and the security is higher. In pharmaceutical component containing docetaxel, docetaxel content is more than 20%, such that the preparation process of pharmaceutical component containing docetaxel is simple, and easy for the industrial applications.

Abstract: The present invention relates to improved pharmaceutical compositions of pharmaceutically active agents, having high bioavailability and to a method for preparing such compositions.

Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

Abstract: This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.